Release Date: February 6, 2026
Expiration Date: March 13, 2026
Activity Overview
We are excited to welcome you to an event designed to integrate the expertise of local practicing medical oncologists, radiation oncologists, and surgeons from Hawaii: The 4th Annual Hawaii Lung: A Multidisciplinary Case-Based Conference®, which is proudly brought to you in partnership with the Hawaii Society of Clinical Oncology and the University of Hawai‘i Cancer Center.
This program consists entirely of case-based panel discussions featuring local Hawaii-based faculty and moderated by key experts from the continental United States. The panels address key aspects of care for patients with early-stage, locally advanced, and metastatic lung cancer.
This educational activity is an archive of the live presentation held on Saturday, January 24, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in lung cancer. Other health care professionals interested in the treatment of lung cancer are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement the latest evidence-based, guideline-preferred approaches to biomarker testing for determining treatment plans for patients with lung cancer
- Integrate emerging clinical trial evidence regarding the management of patients with lung cancer into personalized treatment plans
- Apply best practices for identifying and mitigating treatment-related adverse effects associated with novel therapies for lung cancer
David R. Gandara, MD
Professor of Medicine Emeritus
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
University of California Davis Comprehensive Cancer Center
Adjunct Clinical Professor, Translational and Clinical Research
Program
University of Hawaii Cancer Center
Chief Medical Officer, International Society of Liquid Biopsy
Sacramento, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Adagene, AstraZeneca, Exact Sciences, Foundation Medicine, Genentech, Guardant Health, Henlius, IO Biotech, Janssen, Merck, Mirati, OncoHost, One Carbon, Regeneron, Revolution Medicine, Sanofi
Nicolas Villanueva, MD
Assistant Clinical Professor
Department of Medicine
John A. Burns School of Medicine
University of Hawaiʻi at Mānoa
Clinical Faculty
University of Hawai‘i Cancer Center
Hematology/Oncology
Hawaii Oncology, Inc
Honolulu, HI
Disclosures: Nicolas Villanueva, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here